MOVE: Rounding Bottom detected on 8 Apr 2026

Corvex, Inc. completed an all-stock merger with Movano Inc. on March 19, 2026, and was renamed effective March 23, 2026, continuing to trade under symbol MOVE. The rounding bottom pattern is forming at $12.13 current price, 252.62% above the 52-week low of $3.44 (key support) and 52.76% below the 52-week high. Structure score of 12.5/15 reflects a defined low-point formation. Volume score of 12.0/12 signals exceptional strength—current volume of 1,052,734 shares represents a 9.97x ratio to the 20-day average of 105,581, confirming high institutional accumulation. Breakout score of 13.0/13 suggests the pattern edges toward resolution. Key resistance sits at $5.04; the conservative target is $12.94.

A May 2026 stockholders' meeting will be held to approve leadership with Jay Crystal and Seth Demsey as Co-Chief Executive Officers. Prior to the merger, Corvex and Movano raised $40.2 million to expand the pure-play platform for secure, high-performance AI infrastructure. The AI division reported $4.9 million in revenue for the nine months ended September 30, 2025, and operates Tier III-designed capacity in Delaware. However, the company reports negative net income of -$5.89M and revenue of $44K versus $5.69M operating losses, raising dividend sustainability concerns. A 35.8% stock dividend was distributed on April 6, 2026. The strategic pivot into AI infrastructure is the core catalyst, but pre-merger financials show the legacy healthcare wearables business was minimal—the transformation is in early innings with significant execution risk ahead of the May stockholder vote.

The rounding bottom suggests accumulation and stabilization at multi-year lows before a sustained move higher. A successful breakout above $5.04 resistance would confirm the pattern and project toward the conservative target of $12.94—a 156.3% move from the current price. Volume confirmation remains the critical confirmation signal; the current 9.97x ratio to average is exceptionally strong and should sustain on breakout. The invalidation level sits at $3.44 (key support). Historical win probability of 63.67% indicates this setup has a legitimate edge, though not extreme confidence. The pattern suggests strong accumulation is building despite sector headwinds.

The merger consideration includes 240.562 Series B, 23,551.5195 Series C and 30,227.0524 Series D preferred shares, each convertible into 1,000 common shares upon approval, plus a 0.358-for-1 stock dividend, creating potential dilution of up to 53,778,572 common shares and a material overhang dynamic for existing holders. Conversion of Series C and D preferred stock and board elections are contingent on stockholder approval at the 2026 meeting, creating execution and governance uncertainty if any proposal fails. MOVE's weekly volatility has increased from 36% to 43% over the past year. With beta at 1.64 and a 20-day volatility of 2.58%, MOVE exhibits elevated risk. The healthcare sector regime is bearish. No analyst coverage available. RSI at 57.68 is neutral—no overbought condition, but limited technical buffer. The core risk is execution: can management prove the AI infrastructure business scales profitably before dilutive preferred conversions become accretive to common shareholders?